The Latest Breaking News from AstraZeneca

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

Group profit in the first half of the year spiked by 48% as Michel Demaré lined up for chair

Only one in seven people in low-income countries are fully vaccinated with poorest pushed to the ‘back of the queue’

Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Here's a roundup of top developments in the biotech space over the last 24 hours:

A research team from Mahidol University has estimated that the government's Covid-19 vaccination campaign over the past two years prevented nearly 490,000 deaths.

AZD1390 is under investigation by AstraZeneca, who helped develop a Covid-19 vaccine that has seen more than two billion doses released worldwide

After over two years of COVID-19-induced lockdown, Bhutan will open its doors for tourists on September 23 with a new expensive policy for international tourists and Indians as well. Bhutan Foreign Minister Tandi Dorji says the lessons of COVID-19 include better ties with neighbours, including China.